Tumor ablation is a minimally invasive procedure used to treat malignancies of the bones, kidneys, liver, and lungs. A generator and a needle-shaped device make up the ablation system, which uses heat to trigger acute cellular necrosis in the target cells. By inserting a probe and heating it to 100 degrees Celsius while using Precise Computer Tomography, the treatment eliminates benign tumors without removing them from the body. It can be carried out via Cryoablation, Microwave Ablation, and Radiofrequency Ablation, among other methods. With repeated administrations, it offers reduced patient pain and risk, better precision, and a bigger treatment area.
The technological aspect of the different treatments utilized today to treat deadly cancer primarily drives the tumor ablation market worldwide.
The demand for advanced tumor ablation procedures is anticipated to increase throughout the forecast period as surgeons and patients become more inclined toward minimally invasive procedures due to the advantages of quick recovery, patient comfort, and shorter recovery times. Advanced tumor ablation operations are typically conducted on an outpatient basis. They do not require any hospital admission, considerably lowering the overall cost of healthcare comparing advanced tumor ablation procedures to conventional therapies. The preferred treatment for tumors of lesser sizes is ablative surgery. The yearly cancer screening rates indirectly influence the volume of its procedures. As a result of fewer screening measures implemented by concerned authorities, the number of newly detected cancer cases drastically decreased during the COVID-19 pandemic in 2020, significantly influencing the market.
At a CAGR of 11.81%, the tumor ablation industry is predicted to reach USD 2,459.74 million by 2030.
The growing demand for safer therapeutic choices and the rising incidence of cancer are two key drivers of market expansion. By 2030, the WHO predicts that there will be 10 to 11 million new cases of cancer detected annually around the world. From 2008 to 2030, the rate of new cancer cases is anticipated to rise by more than 80% in low-income nations, compared to 40% in high-income ones. The tumor ablation industry is expected to increase substantially in the upcoming years due to the therapeutic choices that are currently available and the rising demand for minimally invasive and non-invasive treatments.
The drivers enabling market participants to improve and release advanced products continuously are technological developments to improve accuracy, portability, and cost-effectiveness. HIFU, cryoablation, and image-guided equipment are three prominent examples of these technological developments. One of the upcoming approaches that are projected to contribute to market growth significantly is the use of the cooled radiofrequency denervation technique with internally cooled radiofrequency probes to increase the size of the lesion. This procedure makes it possible to completely denervate the sacroiliac joint, which aids in treating pain.
In 2021, radiofrequency tumor ablation technology was the sector with the highest tumor ablation industry share - more than 35.0%. Its advantages, such as specificity and effectiveness in solid tumor ablation procedures in the kidneys and liver, can be credited with the domination. Additionally, by treating numerous tumors simultaneously with radiofrequency ablation, multiple electrodes positioned at various places can increase the procedure's effectiveness. This is anticipated to increase the rate of advanced tumor ablation technology adoption.
The market is divided into categories for kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and other types of cancer. Other cancers are covered in this section, including ENT cancer and bone metastases. It is projected that the availability of cutting-edge techniques and rising cancer prevalence will promote market expansion.
The COVID-19 pandemic disrupted routine care in many healthcare facilities and had an impact on healthcare systems all around the world, putting susceptible cancer patients in danger.
Due to the rapid COVID-19 pandemic outbreak, elective treatment for malignancies of the kidney, liver, bones, and lungs had to be postponed to lower the risk of coronavirus infection via hospital visits or contact with medical personnel or equipment.